摘要
目的:研究奥沙利铂联合卡培他滨治疗结直肠癌疗效及对炎症因子和免疫指标表达水平的影响。方法:选取2020年3月~2023年1月某院收治的结直肠癌患者75例作为研究对象。采用随机信封法分为观察组(38例)和对照组(37例)。对照组采用卡培他滨治疗,观察组采用奥沙利铂联合卡培他滨治疗。比较两组患者中性粒细胞与淋巴细胞比值(NLR)、肿瘤坏死因子-α(TNF-α)、白介素-2(IL-2)、Th1/Th2、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、癌因性疲乏评分、卡氏功能状态评分,比较两组患者临床疗效和不良反应总发生率。结果:治疗后,两组患者NLR和TNF-α降低,且观察组低于对照组(P<0.05);IL-2升高,且观察组高于对照组(P<0.05);CEA和CA19-9下降,且观察组低于对照组(P<0.05);癌因性疲乏评分降低且观察组低于对照组(P<0.05);卡氏功能状态评分升高且观察组高于对照组(P<0.05)。观察组临床总有效率(65.79%)高于对照组(40.54%,P<0.05);不良反应总发生率比较无统计学差异(P>0.05)。结论:与单独用卡培他滨治疗相比,奥沙利铂联合卡培他滨治疗结直肠癌的临床疗效更好,患者血清NLR、CEA和CA19-9水平更低,且不会增加患者不良反应的发生率,值得临床推广应用。
Objective:To investigate the efficacy of oxaliplatin combined with capecitabine in the treatment of colorectal cancer and its effects on the expression of inflammatory and immune markers.Methods:A total of 75 patients with colorectal cancer who were treated in the hospital between March 2020 and January 2023 were selected as the study subjects.The patients were divided into an observation group(n=38)and a control group(n=37)using the random envelope method.The control group was treated with capecitabine,while the observation group was treated with oxaliplatin combined with capecitabine.The therapeutic effect,neutrophil to lymphocyle ratio(NLR),tumor necrosis factor-α(TNF-α),interleukin-2(IL-2),Th1/Th2,carcinoembryonic antigen(CEA),carbohydrate antigen 19-1(CA19-9),cancer-related fatigue score,Karnofsky performance status(KPS)score,treatment effect and adverse drug reactions were compared between the two groups.Results:After treatment,the levels of NLR and TNF-αdecreased in both groups and were lower in the observation group than in the control group(P<0.05);the level of IL-2 increased and was higher in the observation group than in the control group(P<0.05);the levels of CEA and CA19-9 decreased and were lower in the observation group than in the control group(P<0.05);the cancer-related fatigue score decreased and was lower in the observation group than in the control group(P<0.05);the Karnofsky performance status score increased and was higher in the observation group than in the control group(P<0.05);the total response rate was higher in the observation group than in the control group(65.79%vs.40.54%,P<0.05);there was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Compared with capecitabine alone,the combination of oxaliplatin and capecitabine exhibited better clinical efficacy in the treatment of colorectal cancer,as evidenced by significantly lower serum levels of NLR,CEA and CA19-9 and a comparable incidence of adverse reactions in the patients.Therefore,this regimen is worth promotion for clinical use.
作者
胡黎明
姜勇
董延琥
韩建成
HU Li-ming;JIANG Yong;DONG Yan-hu;HAN Jian-cheng(Puyang City People's Hospital,Puyang 457001,China;Peking University First Hospital,Beijing 100034,China)
出处
《中国合理用药探索》
CAS
2023年第12期61-66,共6页
Chinese Journal of Rational Drug Use
